Affiliations: [a] Neurosurgical Department, The Affiliated Hospital of Qingdao University, Qingdao, China
| [b] Neurosurgical Department, Rizhao City Hospital of Traditional Chinese Medicine, Rizhao, China
| [c] Neurosurgical Department, Liaocheng People’s Hospital, Liaocheng, China
Correspondence:
[*]
Correspondence to: Weicheng Yao, Neurosurgical Department, the Affiliated Hospital of Qingdao University, 16 Jiangsu Road, Qingdao 266003, China. Tel.: +86 53282911328; E-mail: lfj10132@yeah.net.
Abstract: Cerebral ischemic stroke may cause a number of adverse neurological complications or behavioral disorders. Moreover, cerebral ischemic stroke is a prevalent disease with limited treatment strategies and may increase chances of developing neurodegenerative diseases, e.g., Alzheimer’s disease, in the future. Therefore, alternative strategies are highly needed for improving the therapy for ischemic stroke. Human bone marrow stroma stem cells, also known as mesenchymal stem cells (hMSC), have a demonstrative role in treating transient cerebral ischemia, yet whether immortalized hMSC may have a better effect than hMSC is unknown. Here, we addressed this question. A rat cerebral ischemia reperfusion (IR) model was used to compare the effects of hMSC and an immortalized hMSC by human telomerase reverse transcriptase (hMSC-TERT). We found that both hMSC and hMSC-TERT similarly attenuated the elevation of serum neuron specific enolase levels after IR. Transplantation with hMSC alleviated cerebral infarction, alleviated brain edema, improved neural function, and reduced brain cell apoptosis, in a significantly better degree than transplantation with hMSC. Thus, these data suggest that immortalized hMSC may have an advantage over hMSC in treatment of transient cerebral ischemia.
Keywords: Apoptosis, cerebral ischemia reperfusion, human bone marrow stroma stem cells
